Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,196 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05161585 | Evaluation of Circulating Tumor DNA Guided Surveillance Strategy of Stage III Colorectal Cancer: an Open, Prospective, Randomized Controlled Cohort Study | unknown | N/A | 316 | Fudan UniversityOTHER | 1 | Dec 17, 2021 | clinicaltrials |
| NCT05141630 | Axillary Sentinel or Targeted Lymph Node Biopsy Alone After Neoadjuvant Chemotherapy in Node-positive Breast Cancer | unknown | Phase 2 | 100 | Fudan UniversityOTHER | 1 | Dec 2, 2021 | clinicaltrials |
| NCT05138159 | A Study of Donafenib Plus S-1 in Treating Patients With Metastatic Pancreatic Cancer After Chemotherapy With Nab-paclitaxel Plus Gemcitabine Regimen | unknown | Phase 2 | 10 | Fudan UniversityOTHER | 1 | Nov 30, 2021 | clinicaltrials |
| NCT05131763 | NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors | unknown | Phase 1 | 3 | Fudan UniversityOTHER | 1 | Nov 23, 2021 | clinicaltrials |
| NCT05124431 | Anlotinib Plus Everolimus as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma(ALTER-UC-001) | unknown | Phase 2 | 30 | Fudan UniversityOTHER | 1 | Nov 18, 2021 | clinicaltrials |
| NCT04939831 | Laparoscopic or Abdominal Radical Hysterectomy for Cervical Cancer(Stage IB3,IIA2)(LAUNCH 3) | unknown | N/A | 1,104 | Obstetrics & Gynecology Hospital of Fudan UniversityOTHER | 1 | Nov 10, 2021 | clinicaltrials |
| NCT04519905 | Phase III Study of Concurrent Radiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma (ESO-Shanghai 15) | recruiting | N/A | 320 | Fudan UniversityOTHER | 1 | Nov 2, 2021 | clinicaltrials |
| NCT04929769 | Laparoscopic or Abdominal Radical Hysterectomy for Cervical Cancer(Stage IB1,IB2,IIA1)(LAUNCH 2) | recruiting | N/A | 780 | Obstetrics & Gynecology Hospital of Fudan UniversityOTHER | 1 | Nov 1, 2021 | clinicaltrials |
| NCT05095636 | Apatinib Monotherapy Versus Apatinib Combined With Camrelizumab for Third-line Treatment of Metastatic Gastric Cancer | unknown | Phase 2 | 102 | Fudan UniversityOTHER | 1 | Oct 27, 2021 | clinicaltrials |
| NCT02395640 | The Comparison of XELOX and EOX in the First-line Treatment of Advanced Gastric Cancer | completed | Phase 3 | 438 | Fudan UniversityOTHER | 1 | Oct 26, 2021 | clinicaltrials |
| NCT04582981 | Fruquintinib and Raltitrexed Versus Fruquintinib Monotherapy in Advanced Colorectal Cancer | unknown | Phase 2 | 136 | Fudan UniversityOTHER | 1 | Oct 26, 2021 | clinicaltrials |
| NCT05059379 | Medial vs. Entire Supraclavicular Lymph Node Radiation Therapy for Patients With Invasive Breast Cancer(SUCLANODE) | recruiting | Phase 3 | 1,650 | Fudan UniversityOTHER | 1 | Oct 25, 2021 | clinicaltrials |
| NCT05092217 | Tirelizumab Plus Surgery vs Surgery Alone for Recurrent Nasopharyngeal Carcinoma | unknown | Phase 2 | 80 | Eye & ENT Hospital of Fudan UniversityOTHER | 0 | Oct 25, 2021 | clinicaltrials |
| NCT05086601 | A Cohort of Molecular Characteristics and Prognosis of Colorectal Cancer | unknown | — | 15,000 | Fudan UniversityOTHER | 1 | Oct 21, 2021 | clinicaltrials |
| NCT05086614 | Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer | recruiting | Phase 3 | 2,500 | Fudan UniversityOTHER | 1 | Oct 21, 2021 | clinicaltrials |
| NCT05076695 | Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast Cancer(NeoTPPF) | unknown | Phase 2 | 37 | Fudan UniversityOTHER | 1 | Oct 13, 2021 | clinicaltrials |
| NCT04781270 | mFOLFOXIRI+Bev vs. mFOLFOX6+Bev for RAS Mutant Unresectable Colorectal Liver-limited Metastases | unknown | Phase 3 | 308 | Fudan UniversityOTHER | 1 | Sep 27, 2021 | clinicaltrials |
| NCT04927611 | Single-cell Sequencing and Establishment of Models in Neuroendocrine Neoplasm | unknown | — | 200 | Fudan UniversityOTHER | 1 | Sep 24, 2021 | clinicaltrials |
| NCT04612439 | Accuracy of VABB Elite 10G Versus BARD 14G CNB | unknown | Phase 3 | 1,470 | Fudan UniversityOTHER | 1 | Sep 14, 2021 | clinicaltrials |
| NCT05032768 | The Association Between Radiation Dermatitis and Skin Microbiome in Breast Cancer Patients | recruiting | — | 100 | Fudan UniversityOTHER | 1 | Sep 2, 2021 | clinicaltrials |
| NCT04948034 | The Combination of Fruquintinib, Tislelizumab and Stereotactic Ablative Radiotherapy in Metastatic Colorectal Cancer(RIFLE) | unknown | Phase 2 | 68 | Fudan UniversityOTHER | 1 | Aug 27, 2021 | clinicaltrials |
| NCT05024019 | Nimotuzumab Combined With Radiotherapy in High-risk Patients With HNSCC Not Suitable for Cisplatin After Surgery | unknown | Phase 2 | 95 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Aug 27, 2021 | clinicaltrials |
| NCT03639168 | Chidamide Combined With Cisplatin in Head and Neck Adenoid Cystic Carcinoma (HNACC) | completed | Phase 2 | 22 | Fudan UniversityOTHER | 1 | Aug 19, 2021 | clinicaltrials |
| NCT05009446 | Single Arm Study of Induction Chemoradiotherapy Combined With Surgery in the Treatment of Locally Advanced SNMM(SNMM) | unknown | Early Phase 1 | 28 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Aug 17, 2021 | clinicaltrials |
| NCT04997837 | Study of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ Adenocarcinoma | recruiting | Phase 3 | 433 | Fudan UniversityOTHER | 1 | Aug 10, 2021 | clinicaltrials |
| NCT04979663 | GEMOX Combined With Donafenib and Tislelizumab in Biliary Tract Cancer | unknown | Phase 1 / Phase 2 | 10 | Fudan UniversityOTHER | 1 | Aug 9, 2021 | clinicaltrials |
| NCT04996446 | ALPPS Combined With Tislelizumab in Liver Malignancy | unknown | Phase 2 | 20 | Fudan UniversityOTHER | 1 | Aug 9, 2021 | clinicaltrials |
| NCT04996459 | Tislelizumab in the Systematic Treatment of Advanced Hepatocellular Carcinoma | unknown | — | 40 | Fudan UniversityOTHER | 1 | Aug 9, 2021 | clinicaltrials |
| NCT04996732 | Long-term Survivorship of Discharged Patients With Malignant Tumor Based on Single-institutional Cancer Registry | recruiting | — | 500,000 | Fudan UniversityOTHER | 1 | Aug 9, 2021 | clinicaltrials |
| NCT04517318 | Treatment After Palbociclib-containing Regimens | completed | — | 200 | Fudan UniversityOTHER | 1 | Aug 3, 2021 | clinicaltrials |
| NCT04555369 | The Value of ctDNA on Chemotherapy Efficacy for mCRC | unknown | N/A | 300 | Fudan UniversityOTHER | 1 | Jul 19, 2021 | clinicaltrials |
| NCT04960943 | Efficacy and Safety of Pyrotinib in HER2 Positive Gastrointestinal Tumors | unknown | Phase 2 | 60 | Fudan UniversityOTHER | 1 | Jul 14, 2021 | clinicaltrials |
| NCT04952103 | Real World Study of Diagnosis and First-line Treatment Among Patients With Cancer of Unknown Primary in China | unknown | — | 200 | Fudan UniversityOTHER | 1 | Jul 7, 2021 | clinicaltrials |
| NCT04947280 | Single Arm Phase II Study of Fractionated Stereotatic Radiation Therapy (FSRT) for Bone Metastases in Breast Cancer | recruiting | Phase 1 / Phase 2 | 120 | Fudan UniversityOTHER | 1 | Jul 1, 2021 | clinicaltrials |
| NCT04517305 | Pyrotinib Plus Vinorelbine in HER2+ Metastatic Breast Cancer Patients | completed | — | 97 | Fudan UniversityOTHER | 1 | Jun 18, 2021 | clinicaltrials |
| NCT04922008 | Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS-C/D) | unknown | Phase 2 | 356 | Fudan UniversityOTHER | 0 | Jun 10, 2021 | clinicaltrials |
| NCT04917276 | Treatment Response Prediction System of mCRC Patients Based on CTC | unknown | — | 100 | Fudan UniversityOTHER | 0 | Jun 8, 2021 | clinicaltrials |
| NCT04917289 | CTC vs Radiography as the Evidence of Recurrence in Colorectal Cancer Patients | unknown | Phase 3 | 100 | Fudan UniversityOTHER | 0 | Jun 8, 2021 | clinicaltrials |
| NCT04913571 | Tislelizumab in Combination With Eribulin for Patients With Metastatic Previously heaviLy-treAted TriplE-negative Breast Cancer:A Prospective Multiple-center Phase II Study(TEMPLATE) | unknown | Phase 2 | 265 | Fudan UniversityOTHER | 1 | Jun 4, 2021 | clinicaltrials |
| NCT04912258 | Preoperative Irinotecan Drug-eluting Beads for Patients With Unresectable Colorectal Liver Metastasis | unknown | Phase 3 | 80 | Fudan UniversityOTHER | 1 | Jun 3, 2021 | clinicaltrials |
| NCT04912882 | Prognosis Predicting of CRC Patients Based on Morphology and Molecular Biomaker of CTC | unknown | — | 1,000 | Fudan UniversityOTHER | 0 | Jun 3, 2021 | clinicaltrials |
| NCT04535024 | The Combination of Immunotherapy and Stereotactic Ablative Radiotherapy in MSS Oligometastatic Colorectal Cancer | unknown | Phase 2 | 60 | Fudan UniversityOTHER | 1 | May 11, 2021 | clinicaltrials |
| NCT04517227 | The Combination Therapy of TACE and Ablation With Durvalumab in Hepatocellular Carcinoma at Intermediate Stage (TAD) | unknown | N/A | 30 | Fudan UniversityOTHER | 0 | May 3, 2021 | clinicaltrials |
| NCT04867330 | Toripalimab Based Induction Chemotherapy Followed by De-escalation Protocols in HPV-related OPSCC | unknown | N/A | 46 | Fudan UniversityOTHER | 1 | Apr 30, 2021 | clinicaltrials |
| NCT04843943 | Sintilimab Combined With Bevacizumab Biosimilar for Potentially Resectable Intermediate HCC | unknown | Phase 1 / Phase 2 | 30 | Fudan UniversityOTHER | 0 | Apr 14, 2021 | clinicaltrials |
| NCT03403101 | The Combination Chemotherapy of SIRIOX as First- or Second-Line Chemotherapy for Pancreatic Cancer | unknown | Phase 2 | 65 | Fudan UniversityOTHER | 1 | Apr 9, 2021 | clinicaltrials |
| NCT04835064 | Pancreatic Cancer With Elevated Serum CA125 Were Compared With Those Who Did Not Receive Neoadjuvant Chemotherapy. | unknown | Phase 3 | 600 | Fudan UniversityOTHER | 0 | Apr 8, 2021 | clinicaltrials |
| NCT04832776 | FOLFOXIRI Plus Cetuximab Versus FOLFOXIRI Plus Bevacizumab in Conversion Therapy of Right-sided Colon Cancer Liver Metastases | unknown | Phase 2 | 160 | Fudan UniversityOTHER | 1 | Apr 6, 2021 | clinicaltrials |
| NCT04833036 | c-CetuIRI Versus Ersecond-line Irinotecan s-IRI-CetuIRI | unknown | Phase 2 | 120 | Fudan UniversityOTHER | 1 | Apr 6, 2021 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials